Review of the cost of venous thromboembolism.
TLDR
Costs for VTE treatment are considerable and increasing faster than general inflation for medical care services, with hospitalization costs being the primary cost driver.Abstract:
Background
Venous thromboembolism (VTE) is the second most common medical complication and a cause of excess length of hospital stay. Its incidence and economic burden are expected to increase as the population ages. We reviewed the recent literature to provide updated cost estimates on VTE management.read more
Citations
More filters
Guanella R, Ducruet T, Johri M, et al. Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation
Raphaël Guanella,Thierry Ducruet,Mira Johri,Marie-José Miron,Andre Roussin,Sylvie Desmarais,F. Joyal,Jeannine Kassis,Susan Solymoss,Jeffrey S. Ginsberg,Donna L. Lamping,Ian Shrier,Susan R. Kahn +12 more
TL;DR: In this paper, the authors evaluated the long-term economic consequences of deep vein thrombosis (DVT) and identified clinical determinants of costs, including medical and non-medical resource use and costs related to DVT during 2 years following diagnosis.
Journal ArticleDOI
If some is good, more is better: An enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis
TL;DR: Implementation of a new, categorized, weight-based enoxaparin dosing protocol was safe and significantly improved the percentage of trauma patients with in-target anti-Xa levels on initial assessment, and further studies are needed to determine whether such dosing decreases venous thromboembolism rates.
Journal ArticleDOI
Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients: A Policy Statement From the American Heart Association
Peter K. Henke,Susan R. Kahn,Christopher J. Pannucci,Eric A. Secemksy,Natalie S Evans,Alok A. Khorana,Mark A. Creager,Aruna D. Pradhan +7 more
TL;DR: From this summary, 5 major areas of policy guidance are presented that the American Heart Association believes will lead to better implementation, tracking, and prevention of VTE events.
Journal ArticleDOI
Venous thromboembolism in inflammatory bowel disease
Kimberly Cheng,Adam S. Faye +1 more
TL;DR: An overview of patient specific factors that affect VTE risk, elucidate reasons for lack of VTE prophylaxis among hospitalized IBD patients, and focus on recent data describing those at highest risk for recurrent VTE post-hospital discharge are provided.
Journal ArticleDOI
Incidence of venous thromboembolism in Korea from 2009 to 2013.
TL;DR: The ASR of VTE in Korea continuously increased from 2009 to 2013, reflecting an increased awareness and detection of V TE as well as improved survival of patients with cancer and other morbidities.
References
More filters
Journal ArticleDOI
Prevention of Venous Thromboembolism* American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition)
William H. Geerts,David Bergqvist,Graham F. Pineo,John A. Heit,Charles M. Samama,Michael R. Lassen,Clifford W. Colwell +6 more
TL;DR: This article discusses the prevention of venous thromboembolism (VTE) and is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Journal ArticleDOI
Dabigatran versus warfarin in the treatment of acute venous thromboembolism
Sam Schulman,Clive Kearon,Ajay K. Kakkar,Patrick Mismetti,Sebastian Schellong,Henry Eriksson,David Baanstra,Janet Schnee,Samuel Z. Goldhaber,S. Schul +9 more
TL;DR: For the treatment of acute venous thromboembolism, a fixed dose of dabigatran is as effective as warfarin, has a safety profile that is similar to that of warfar in, and does not require laboratory monitoring.
Journal ArticleDOI
The Epidemiology of Venous Thromboembolism
TL;DR: Early mortality after VTE is strongly associated with presentation as PE, advanced age, cancer, and underlying cardiovascular disease, with a significantly higher incidence among Caucasians and African Americans than among Hispanic persons and Asian‐ Pacific Islanders.
Journal ArticleDOI
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli,Harry R. Buller,Alexander T. Cohen,Madelyn Curto,Alexander Gallus,Margot Johnson,Urszula Masiukiewicz,Raphael Pak,John F. Thompson,Gary E. Raskob,Jeffrey I. Weitz +10 more
TL;DR: A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding.
Journal ArticleDOI
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Buller,Hervé Decousus,Michael A. Grosso,Saskia Middeldorp,Martin H. Prins,Gary E. Raskob,Sebastian Schellong,Annelise Segers,Minggao Shi,Peter Verhamme,Phil Wells +10 more
TL;DR: Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism.
Related Papers (5)
Oral rivaroxaban for symptomatic venous thromboembolism
Rupert Bauersachs,Scott D. Berkowitz,Benjamin Brenner,Harry R. Buller,Hervé Decousus,Alexander Gallus,Anthonie W. A. Lensing,Frank Misselwitz,Martin H. Prins,Gary E. Raskob,Annelise Segers,Peter Verhamme,Phil Wells,Giancarlo Agnelli,Henri Bounameaux,Alexander T. Cohen,Bruce L. Davidson,Franco Piovella,Sebastian Schellong +18 more